Matthew Trump, DO
Pulmonary Disease · West Des Moines, IANPI 1538321054
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.8%), education and consulting fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Fisher & Paykel Healthcare Inc at 48.1% of the total. Reporting peaked in 2023 at $21,163 and has fallen 74.1% since, to $5,474 in 2025. Among pulmonary disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $622.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fisher & Paykel Healthcare Inc$20K
- Intuitive Surgical$13K
- Olympus America Inc.$6K
- Veran Medical Technologies, Inc.$2K
- Genentech USA, Inc.$265
- Boehringer Ingelheim$213
- plus $163 from 3 others
Across 38 payments — averaging $24,415 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$516K
- Astrazeneca UK Limited$271K
- AstraZeneca$141K
- Novartis$69
What the payments were for
- Consulting fees$6,00015%
- Speaking & faculty fees$18,39145%
- Travel & lodging$4,09410%
- Food & beverage$2,5766%
- Education$10,03024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fisher & Paykel Healthcare Inc | 18 | $19,777 |
| Intuitive Surgical | 18 | $12,994 |
| Olympus America Inc. | 8 | $6,108 |
| Veran Medical Technologies, Inc. | 10 | $1,570 |
| Genentech USA, Inc. | 2 | $265 |
| Boehringer Ingelheim | 6 | $213 |
| KARL Storz Endoscopy-america | 2 | $119 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FISHER & PAYKEL HEALTHCARE$37,917
- Da Vinci Surgical System$9,664
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment$7,391
- Always-On Tip Tracked Forceps, 1.8mm OD, Serrated Cup$6,000
- SPiN Perc Localization Needle 19ga x 105mm, 1cm marking zone$6,000
- PT101US/Airvo 2$4,500
- OPT944/Optiflow Nasal Cannula$4,500
- OPT1044/Optiflow 3S Nasal Cannula$4,500
- 900PT561/Airvo 2 Air Spiral Tube/Chamber Kit$4,500
- OPT970/Optiflow Tracheostomy Interface$4,500
- ION$3,000
- Spin$1,307
- Spiration Valve System$108
- OFEV$102
How this compares
$41,091 in reported general payments places this provider in the 95th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 379 | $355,600 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 191 | $152,791 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 147 | $103,814 |
| Dupixent SyringeDupilumab | 15 | $55,514 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $44,632 |
| Incruse ElliptaUmeclidinium Bromide | 95 | $34,007 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $28,877 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 99 | $24,872 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $22,702 |
| XareltoRivaroxaban | 24 | $21,034 |
| Spiriva HandihalerTiotropium Bromide | 17 | $20,897 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $17,437 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $16,481 |
| Spiriva RespimatTiotropium Bromide | 20 | $14,481 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 89 | $13,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $213 | $183,753232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in West Des Moines
- Dustin McCannWest Des Moines$67K
- James MallenWest Des Moines$16K
- Samantha Danielson-JonesWest Des Moines$11K
- Ryan BrimeyerWest Des Moines$9K
- Amerlon EnriquezWest Des Moines$7K
- Daniel DodgeWest Des Moines$6K
- Ryan MertensWest Des Moines$6K
- John ScottWest Des Moines$3K
- Katrina GuestWest Des Moines$1K
- Gregory HicklinWest Des Moines$422
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.